Study design
NF1
This is a multicenter, open-label, single-arm, non-randomized, phase I dose-escalation trial to evaluate the safety, tolerability, pharmacokinetic (PK), and anti-tumor activity of orally administered FCN-159 in adult patients with NF1 (NCT04954001). Phase I commenced with dose escalation in adult patients following a standard 3 + 3 design (Supplementary Table S